Key products and emerging markets struggle to offset Nycomed's pantoprazole losses
This article was originally published in Scrip
Executive Summary
Strong growth of key products and in emerging markets was not enough to offset the impact of pantoprazole's patent expiry in Nycomed's first quarter ended 31 March. Turnover decreased by 8% to €776 million compared with the same period last year while adjusted EBITDA decreased by 24% to €233 million.